Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 2/20 | 0.48 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.48 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.48 |
| ▸ | FAAH | O00519 | 4/20 | 0.48 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.46 |
| ▸ | CASP2 | P42575 | 1/20 | 0.44 |
| ▸ | GLP1R | P43220 | 8/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17381386 | 1.00 | LPAR1 (0.48) | LPAR1LPAR2ENPP2FAAHDNM1 | |
| SCHEMBL26032382 | 1.00 | LPAR1 (0.48) | LPAR1LPAR2ENPP2FAAHDNM1 | |
| SCHEMBL17481272 | 1.00 | LPAR1 (0.48) | LPAR1LPAR2ENPP2FAAHDNM1 | |
| SCHEMBL17480750 | 1.00 | LPAR1 (0.48) | LPAR1LPAR2ENPP2FAAHDNM1 | |
| SCHEMBL17480732 | 1.00 | LPAR1 (0.48) | LPAR1LPAR2ENPP2FAAHDNM1 | |
| SCHEMBL26031849 | 0.99 | LPAR1 (0.49) | LPAR1LPAR2ENPP2FAAHDNM1 | |
| SCHEMBL29452140 | 0.99 | LPAR1 (0.46) | LPAR1LPAR2ENPP2FAAHDNM1 | |
| SCHEMBL24209427 | 0.97 | LPAR1 (0.47) | LPAR1LPAR2ENPP2FAAHDNM1 | |
| SCHEMBL24390290 | 0.94 | LPAR1 (0.41) | LPAR1LPAR2ENPP2FAAHDNM1 | |
| SCHEMBL17381388 | 0.90 | LPAR1 (0.41) | LPAR1LPAR2ENPP2FAAHDNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199701-A1 | IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199701-A1 | IMMUNOMODULATORS | CD274, PDCD1, PDCD1LG2 | LPAR1 1733/4885LPAR2 2658/4885ENPP2 2042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.